London, UK

Content Library

  • Download Post Event Report

    The inaugural Complement-based Drug Development Summit (Boston, 2017) provided a comprehensive, end-to-end analysis of the drug research and development process in this space,  from the fundamental science and clinical trial design through to safety assessment and gaining regulatory approval.

    Each discussion was led by insights from our expert speaker faculty of C-level executives, SVPs, Senior Directors and key academics from the leading companies and institutions advancing complement therapeutics.

    The summit brought together over 150 experts to share and discuss the latest clinical trial data from the likes of Alexion, Apellis, Ra Pharma, Bioverativ, Genentech, GSK and many more.